- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05909228
Bone Markers in Pediatric IF
Bone Turnover Markers in Children With Intestinal Failure After Optimization of Parenteral Nutrition
Study Overview
Status
Conditions
Detailed Description
It is currently unknown if optimization of PN mixtures leads to a measurable change in bone turnover markers. Our hypothesis is that bone turnover markers of children with IF whose PN has been optimized will not differ from those of healthy control subjects, with a positive effect on bone mineral density.
Our aims are:
- To measure bone turnover markers in children with IF on long-term PN and compare them with age- and sex-matched healthy children who never received PN
- To evaluate if changes in bone turnover markers are related to changes in bone mineral density measured by Dual energy X-ray absorptiometry (DXA)
- To identify IF- and PN-related factors associated with bone health
To be able to answer these aims, bone markers in children with IF will be compared to bone markers in healthy controls, age- and sex-matched.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria are as follows:
In order to be eligible to participate in this study, a patient must meet all of the following criteria at time of inclusion:
- Consent provided
- Age < 18 years
- Suffering from IF needing PN providing at least 25% of calories for ≥6 weeks
- Medically stable with no acute changes in condition requiring hospitalization, or other intervention at home (for at least 3 months).
For healthy controls the inclusion criteria are as follows:
- Consent provided
- Age < 18 years.
A patient who meets any of the following criteria will be excluded from participation in this study:
- On PN for < 6 weeks
- Suffering from an acute clinical event, for example gastroenteritis, colds and flu
- Suffering from sepsis on antibiotics
- On medication known to affect bone metabolism, for example steroids
- Having a history of fracture within the last 12 months.
For healthy controls, the exclusion criteria are as follows:
- Any condition known to affect bone health (chronic disease, bone disease, history of malignancy, radiotherapy, steroid use, mental or physical disability)
- A positive history of fractures within the past 2 years
- Poor growth (weight- and height-for-age below - 2 or above + 2 standard deviation score using the WHO growth charts).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Children with intestinal failure
Children with intestinal failure on parenteral nutrition
|
|
Healthy controls
Healthy controls without parenteral nutrition
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone turnover markers - Osteocalcin
Time Frame: Baseline
|
To measure serum osteocalcin levels in children with intestinal failure on long-term parenteral nutrition and compare them with age- and sex-matched healthy children who never received parenteral nutrition.
|
Baseline
|
|
Bone turnover markers - C-telopeptide
Time Frame: Baseline
|
To measure serum C-telopeptide levels in children with intestinal failure on long-term parenteral nutrition and compare them with age- and sex-matched healthy children who never received parenteral nutrition.
|
Baseline
|
|
Bone turnover markers - Bone-specific alkaline phosphatase
Time Frame: Baseline
|
To measure serum bone-specific alkaline phosphatase levels in children with intestinal failure on long-term parenteral nutrition and compare them with age- and sex-matched healthy children who never received parenteral nutrition.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone health
Time Frame: DXA scan results will be collected when performed within 6 months of the blood draw for the bone markers.
|
Association of serum osteocalcin, C-telopeptide and bone-specific alkaline phosphatase with bone mineral density Z-scores for lumber spine and total body less head obtained from DXA scans performed as standard clinical care.
|
DXA scan results will be collected when performed within 6 months of the blood draw for the bone markers.
|
|
Intestinal failure and parenteral nutrition related factors
Time Frame: Baseline
|
Association of intestinal failure and parenteral nutrition related factors such as duration of parenteral nutrition (y) with serum osteocalcin, C-telopeptide and bone-specific alkaline phosphatase levels.
|
Baseline
|
|
Intestinal failure and parenteral nutrition related factors
Time Frame: Intestinal failure and parenteral nutrition related factors
|
Association of intestinal failure and parenteral nutrition related factors such as parenteral nutrition dependency index (%) with serum osteocalcin, C-telopeptide and bone-specific alkaline phosphatase levels.
|
Intestinal failure and parenteral nutrition related factors
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Glenda Courtney-Martin, PhD, RD, The Hospital for Sick Children
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000080417
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.